N4 Pharma PLC Result of AGM (0451P)
May 23 2018 - 6:31AM
UK Regulatory
TIDMN4P
RNS Number : 0451P
N4 Pharma PLC
23 May 2018
N4 Pharma Plc
Result of meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
which improves the delivery of existing drugs and novel vaccines
and therapeutics, announces that at its Annual General Meeting held
earlier today, all resolutions were duly passed.
Enquiries:
N4 Pharma Via Alma PR
CEO, Nigel Theobald
Stockdale Securities Tel: +44(0)207 601
Tom Griffiths 6100
Alma PR Tel: +44(0)778 090
Josh Royston 1979
Robyn Fisher Tel: +44(0)754 070
6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company which
reformulates existing drugs and vaccines to improve their
performance.
N4 Pharma's reformulation work falls under two divisions:
-- generic, already commercialised, drugs; and
-- delivery of novel and existing vaccines and therapeutics.
N4 Pharma has identified a number of established drugs that
could be improved upon through its reformulation techniques. N4
Pharma's most advanced reformulation is for sildenafil, widely
marketed as Viagra(TM), where N4 Pharma is seeking to improve the
speed at which the drug takes effect whilst also extending its
duration of action.
N4 Pharma's reformulation approach should take approximately
three years to obtain regulatory approval as opposed to the
traditional process for new drugs of on average ten years. The cost
and risk profile of this model is also significantly less than the
traditional process. N4 Pharma's business model for generics is to
take reformulated drugs from its portfolio through to the stage
where it will license its newly reformulated drugs to
pharmaceutical companies to commercialise them. N4 Pharma's
revenues should be derived from up front milestone and royalty
payments associated with the licence.
N4 Pharma's business model for vaccines is to undertake the
required clinical work to demonstrate the capability of its
delivery system as a cancer vaccine or therapeutic treatment so
that it can license the technology to major players developing
treatments in this area, again in return for up front milestone and
royalty payments associated with the licence.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGBGGDUGXDBGIX
(END) Dow Jones Newswires
May 23, 2018 06:31 ET (10:31 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024